Clinical Trials Logo

Filter by:
NCT ID: NCT05804929 Recruiting - Health Behavior Clinical Trials

Phenotypic Characteristics of Superlean Individuals Including Gut Microbiome

Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to build on our previous work to further characterise the phenotype of superlean individuals (BMI < 18.5) when compared to normal BMI people (BMI 21.5 to 25). This will include characterising the body composition, food intake behaviour, circulating hormone levels, genetics and characteristics of the gut microbiota. The investigators expect to recruit up to 200 healthy superlean and control volunteers respectively,

NCT ID: NCT05804916 Recruiting - Breast Cancer Clinical Trials

Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer

Start date: April 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a single-center,blinded, efficacious, phase III randomized clinical trial initiated by investigators. The primary objective is to investigate the use of Surface Guided Radiation Therapy (SGRT) in combination with Deep Inspiration Breath Hold (DIBH) technique for left breast cancer treatment, compared to traditional laser alignment with free breathing treatment. This approach offers superior positioning accuracy and improved heart protection without any increase in radiation or adverse reactions.

NCT ID: NCT05804526 Recruiting - Clinical trials for Advanced Solid Tumours

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Start date: July 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate safety , clinical pharmacology and efficacy of intravenous RC88 combined with Sintilimab in advancedsolid tumours

NCT ID: NCT05804071 Recruiting - Clinical trials for Iron Deficiency Anemia of Pregnancy

Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy

Start date: March 28, 2023
Phase: Phase 4
Study type: Interventional

Subjects were tested for hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count during routine prenatal examination at 24-26 weeks of gestation, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. Those who met the criteria were included in the study group, signed the informed consent form and randomized into groups, and were given different drug administration schemes (150mg orally every day, 300mg orally every day, 150mg orally every other day, 300mg orally every other day, intravenous). At the same time, each subject was given anemia diet education, and all subjects were given folic acid 400ug/d and vitamin C 0.5g/d orally during the treatment period. If the subjects were in the oral iron group, the same time of oral iron was determined as 20 o'clock ± 1 hour in the evening, and the oral iron was not taken with other drugs; If the subject is in the intravenous medication group, the medication is scheduled to be administered at a uniform time of 8 o'clock ± 1 hour in the morning. The above subjects were followed up. Hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count were performed at 30-32 and 37 weeks of pregnancy and delivery, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. The adverse reactions were investigated with a questionnaire at the last prenatal examination before delivery. After full term delivery, the patient fills in the delivery information and enters it into the database. Finally, the data statistician and the above personnel used the blind method for statistical analysis and reached a conclusion.

NCT ID: NCT05803746 Recruiting - Colorectal Cancer Clinical Trials

PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

Start date: July 15, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to construct a noninvasive approach using 68Ga- Mirc415 PET/CT to detect the PD-L2 expression of tumor lesion in patients with colorectal cancer, lung cancer and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.

NCT ID: NCT05803564 Recruiting - Clinical trials for Thoracoabdominal; Aortic, Aneurysm, Dissecting

Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

A First in man study to evaluate the safety and efficacy of thoracoabdominal aortic stent system for endovascular treatment of thoracoabdominal aortic dissecting aneurysm.

NCT ID: NCT05803239 Recruiting - Clinical trials for Mediastinal Lymphadenopathy

Study on Transbronchial Ultrasound-guided Cryobiopsy in the Diagnosis of Mediastinal Lymphadenopathy

Start date: April 2, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the diagnostic effcacy and safety of transbronchial ultrasound-guided cryobiopsy in the diagnosis of mediastinal lymphadenopathy. The main question it aims to answer are: the effectiveness and safety of transbronchial ultrasound-guided cryobiopsy in the diagnosis of mediastinal lymphadenopathy. Participants will undergo transbronchial ultrasound-guided cryobiopsy (EBUS-TBCB) and endobronchial ultrasound-guided trans-bronchial needle aspiration (EBUS-TBNA).

NCT ID: NCT05803187 Recruiting - Plaque Psoriasis Clinical Trials

Clinical Study of Stage IV Psoriasis in Children With Geleli

Start date: April 5, 2023
Phase:
Study type: Observational

This study is a multicenter, prospective, observational phase IV clinical study. A total of 80 children and adolescents with severe plaque psoriasis were included in the study. The study is expected to last for 24 weeks (169 days). This study will evaluate the efficacy and safety of Valerie ® (Adalimumab Injection) in Chinese children over 4 years old and adolescents with severe plaque psoriasis.

NCT ID: NCT05803148 Recruiting - Syncope, Vasovagal Clinical Trials

Treatment Strategy of Vasovagal Syncope

CAMPAIGN
Start date: April 5, 2023
Phase: N/A
Study type: Interventional

This is a prospective, international multi-center, open-labeled, randomized trial. The investigator speculated that CNA prevents more patients with moderate to severe VVS from syncope recurrence compared to midodrine.

NCT ID: NCT05803057 Recruiting - Glioma Clinical Trials

Accelerating Motor Recovering in Patients With SMA Syndrome After Glioma Surgery by Using nrTMS

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized clinical controlled trial is to learn about whether neuro-navigation repetitive transcranial magnetic stimulation (nrTMS) was useful to accelerate the recovery in patients with SMA syndrome after glioma resection. The main questions aim to answer: - Question 1: Whether the nrTMS was useful to accelerate the recovery of motor function back to the preoperative status in participants with SMA syndrome after glioma resection. - Question 2: Whether the nrTMS was useful to improve postoperative motor function in participants with SMA syndrome after glioma resection. Participants will continue to receive nrTMS treatment or nrTMS sham-treatment for 7 times on the 8th day after glioma resection to determine whether the TMS was helpful for exercise rehabilitation. The investigator will evaluate the effects of nrTMS treatment through the ratio of recovery of motor function and the time that was from the participants suffering SMA syndrome to totally recover the motor function to the status of motor function in pre-operation.